Mednax, Inc. (MD): Price and Financial Metrics


Mednax, Inc. (MD)

Today's Latest Price: $23.60 USD

0.31 (-1.30%)

Updated Jan 15 7:00pm

Add MD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 77 in Medical - Services

See all "A" rated Strong Buy stocks

MD Stock Summary

  • Mednax Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 85.55% of US listed stocks.
  • Revenue growth over the past 12 months for Mednax Inc comes in at -23.15%, a number that bests just 15.57% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MD comes in at 10.35% -- higher than that of 83.78% of stocks in our set.
  • Stocks that are quantitatively similar to MD, based on their financial statements, market capitalization, and price volatility, are BBCP, HMTV, TTMI, PACK, and SUM.
  • Visit MD's SEC page to see the company's official filings. To visit the company's web site, go to www.mednax.com.

MD Stock Price Chart Interactive Chart >

Price chart for MD

MD Price/Volume Stats

Current price $23.60 52-week high $27.86
Prev. close $23.91 52-week low $7.37
Day low $23.44 Volume 419,400
Day high $24.05 Avg. volume 1,027,890
50-day MA $21.58 Dividend yield N/A
200-day MA $17.75 Market Cap 2.02B

Mednax, Inc. (MD) Company Bio


MEDNAX Inc. provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company was founded in 1979 and is based in Sunrise, Florida.

MD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$23.60$10.51 -55%

We started the process of determining a valid price forecast for Mednax Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Mednax Inc ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 55.17%. The most interesting components of our discounted cash flow analysis for Mednax Inc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is -5.34 -- which is good for besting only 12.87% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • Its compound free cash flow growth rate, as measured over the past 5.53 years, is -0.04% -- higher than merely 19.21% of stocks in our DCF forecasting set.
  • Mednax Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-56%
1%-56%
2%-55%
3%-55%
4%-55%
5%-54%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MD, try GILD, A, BIO, RGEN, and BAX.


MD Latest News Stream


Event/Time News Detail
Loading, please wait...

MD Latest Social Stream


Loading social stream, please wait...

View Full MD Social Stream

Latest MD News From Around the Web

Below are the latest news stories about Mednax Inc that investors may wish to consider to help them evaluate MD as an investment opportunity.

Here's Why You Should Hold MEDNAX (MD) in Your Portfolio Now

Riding high on its strategic efforts and cost-cutting measures, MEDNAX (MD) holds enough potential to reap benefits for investors.

Yahoo | January 15, 2021

NAPA Management Services Corporation -- Moody's announces completion of a periodic review of ratings of NAPA Management Services Corporation

Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of NAPA Management Services Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 11 January 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

Yahoo | January 14, 2021

MEDNAX, Inc. -- Moody's announces completion of a periodic review of ratings of MEDNAX, Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of MEDNAX, Inc. New York, January 14, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of MEDNAX, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 11 January 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

Yahoo | January 14, 2021

NAPA Management Services Corporation -- Moody's upgrades NAPA's CFR to Caa1, appends /LD indicator to PDR, outlook stable

Moody's Investors Service ("Moody's") upgraded NAPA Management Services Corporation's ("NAPA") Corporate Family Rating (CFR) to Caa1 from Caa2, Probability of Default Rating (PDR) to Caa1-PD/LD from Caa2-PD and the senior secured first lien debt rating to B3 from Caa1. In the second quarter of 2020, NAPA amended its second lien credit agreement (not rated) in a manner that allowed it to pay the interest on its second lien term loan in kind, rather than in cash. Moody's appended the /LD indicator to the Probability of Default Rating as the amendment resulted in terms less favorable than that provided in the original credit agreement.

Yahoo | December 22, 2020

MEDNAX, Inc. -- Moody's confirms MEDNAX's B1 CFR, outlook positive

Moody's Investors Service ("Moody's") confirmed MEDNAX, Inc.'s ("MEDNAX") B1 Corporate Family Rating (CFR), the B1-PD Probability of Default Rating and the B1 unsecured global note ratings and changed the outlook to positive from rating under review. In addition, Moody's upgraded the Speculative Grade Liquidity rating (SGL) to SGL-1 from SGL-2.

Yahoo | December 18, 2020

Read More 'MD' Stories Here

MD Price Returns

1-mo -1.99%
3-mo 74.81%
6-mo 24.21%
1-year -14.77%
3-year -55.90%
5-year -65.04%
YTD -3.83%
2020 -11.69%
2019 -15.79%
2018 -38.25%
2017 -19.83%
2016 -6.98%

Continue Researching MD

Here are a few links from around the web to help you further your research on Mednax Inc's stock as an investment opportunity:

Mednax Inc (MD) Stock Price | Nasdaq
Mednax Inc (MD) Stock Quote, History and News - Yahoo Finance
Mednax Inc (MD) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8002 seconds.